We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ciphergen and Sanofi-Aventis Announces Pharmaceutical Biomarker Research Collaboration
News

Ciphergen and Sanofi-Aventis Announces Pharmaceutical Biomarker Research Collaboration

Ciphergen and Sanofi-Aventis Announces Pharmaceutical Biomarker Research Collaboration
News

Ciphergen and Sanofi-Aventis Announces Pharmaceutical Biomarker Research Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ciphergen and Sanofi-Aventis Announces Pharmaceutical Biomarker Research Collaboration "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ciphergen has announced that it has extended its existing relationship with sanofi-aventis  by signing a collaborative research agreement. The project will concentrate on discovery, validation, and identification of biomarkers for a pre-clinical drug efficacy study in the field of oncology.

Under the terms of the agreement, Ciphergen will analyze samples at one of its Biomarker Discovery Center® laboratories using its suite of proteomic solutions (Pattern Track™ Process, and ProteinChip® System).

"We are extremely pleased to be partnering with sanofi-aventis, an organization committed to innovation which shares our vision to accelerate and streamline development of new drugs through the early identification of relevant drug efficacy biomarkers," stated Gail S. Page, President and CEO of Ciphergen.

"The partnership allows sanofi-aventis access to our expert scientists and latest technologies and is an important addition to our translational proteomics partnerships for drug discovery and development."

Advertisement